This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
Save the dateMarch 17–19, 2025 | Milan, Italy

T-knife Therapeutics


T-knife is creating next-generation T cell therapies for patients with solid tumor cancers. The company's unique approach leverages its MyT platform, a T cell receptor and target identification platform, along with proprietary next-generation enhancements to drive deeper, more durable responses for patients. T-knife is developing a pipeline of TCR-T product candidates; the company's first generation program targeting MAGE-A1 demonstrated safety and POC of the platform in a Phase 1a study. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin. The company has raised nearly $200M to date from leading life sciences investors, and is based in the US and in Germany.